我国慢性丙型肝炎患者真实世界中直接抗病毒药物治疗方案的选择与评价

安子英; 丁洋; 窦晓光

doi:10.3969/j.issn.1001-5256.2018.02.003

我国慢性丙型肝炎患者真实世界中直接抗病毒药物治疗方案的选择与评价

DOI: 10.3969/j.issn.1001-5256.2018.02.003

中国医科大学附属盛京医院感染科

详细信息

中图分类号: R512.63
计量
- 文章访问数: 2464
- HTML全文浏览量: 35
- PDF下载量: 572
- 被引次数: 0
出版历程
- 出版日期: 2018-02-20

Selection and evaluation of treatment regimens with direct-acting antiviral agents for patients with chronic hepatitis C in the real world in China

Department of Infectious Diseases, Shengjing Hospital of China Medical University

摘要

摘要:
慢性丙型肝炎是一种世界范围流行的慢性进展性疾病,严重威胁人类健康,直接抗病毒药物(DAA)的上市为其治疗带来了革命性的变化。近年来国外已上市多种DAA并取得了良好的疗效,我国亦已陆续批准上市数种并广泛应用于临床,使丙型肝炎治愈率显著上升。通过对我国已上市药物的特点、临床疗效及适应证进行分析,结合已经发表的真实世界中的研究,帮助临床医生根据患者疾病的特点,选择合适的治疗方案。
- 肝炎,丙型,慢性 /
- 抗病毒药 /
- 治疗 /
- 真实世界
Abstract:
Chronic hepatitis C (CHC) is a chronic and progressive disease prevalent in the whole world and greatly threatens human health.The launch of direct-acting antiviral agents (DAAs) brings a revolutionary change in the treatment of CHC.In recent years, several DAAs have been marketed in foreign countries and have achieved good clinical effects, and in China, some DAAs have also been approved and widely used in clinical practice, which contributes to the increase in the cure rate of hepatitis C.This article analyzes the features, clinical effects, and indications of DAAs marketed in China and reviews published real-world studies, in order to help clinicians select proper treatment regimens based on patients' features.
- hepatitis C, chronic /
- antiviral agents /
- therapy /
- real-world

HTML全文

参考文献(25)

[1]MESSINA JP, HUMPHREYS I, FLAXMAN A, et al.Global distribution and prevalence of hepatitis C virus genotypes[J].Hepatology, 2015, 61 (1) :77-87.

[2]TANG L, MARCELL L, KOTTILIL S.Systemic manifestations of hepatitis C infection[J].Infect Agent Cancer, 2016, 11:29.

[3]BELOUSOVA V, ABDRABOU AA, MOUSA SA.Recent advances and future directions in the management of hepatitis C infections[J].Pharmacol Ther, 2015, 145:92-102.

[4]TAMORI A, ENOMOTO M, KAWADA N.Recent advances in antiviral therapy for chronic hepatitis C[J].Mediators Inflamm, 2016, 2016:6841628.

[5]ELBAZ T, EL-KASSAS M, ESMAT G.New era for management of chronic hepatitis C virus using direct antiviral agents:a review[J].Adv Res, 2015, 6:301-310.

[6]SORIANO V, LABARGA P, de MENDOZA C, et al.New hepatitis C therapies for special patient populations[J].Expert Opin Pharmaco, 2016, 17 (2) :217-229.

[7]PASQUINELLI C, MCPHEE F, ELEY T, et al.Single-and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C[J].Antimicrob Agents Chemother, 2012, 56 (4) :1838-1844.

[8]NAKAMURA M, KANDA T, HAGA Y, et al.Sofosbuvir treatment and hepatitis C virus infection[J].World J Hepatol, 2016, 8 (3) :183-190.

[9]BHAMIDIMARRI KR, MARTIN P.Finally, safe and effective treatment options for hepatitis C in hemodialysis patients[J].J Hepatol, 2016, 7 (65) :40-47.

[10]LAGRUTTA A, ZENG H, IMREDY J, et al.Interaction between amiodarone and hepatitis-C virus nucleotide inhibitors in human induced pluripotent stem cell-derived cardiomyocytes and HEK-293 Cav1.2 over-expressing cells[J].Toxicol Appl Pharmacol, 2016, 308:66-76.

[11]BRAINARD DM, Mc HUTCHISON JG.Bradyarrhythmias associated with sofosbuvir treatment[J].N Engl J Med, 2015, 373:1888.

[12]MACDONALD A, HARRIS M.Hepatitis C virus NS5A:tales of a promiscuous protein[J].J Gen Virol, 2004 (85) :2485-2502.

[13]POORDAD F, SCHIFF ER, VIERLING JM, et al.Daclatasvir with sofosbuvir and ribavirin for HCV infection with advanced cirrhosis or post-liver transplant recurrence[J].Hepatology, 2016, 63 (5) :1493-1505.

[14]JI D, CHEN GF, WANG C, et al.Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients[J].Hepatol Int, 2016, 10 (5) :798-798.

[15]AN ZY, SHENG QJ, DING Y, et al.Early efficacy and safety of direct-acting antiviral agents for the treatment of cirrhotic patients with hepatitis C[J].Infect Dis Info, 2016, 29 (2) :81-84, 96. (in Chinese) 安子英, 盛秋菊, 丁洋, 等.直接抗病毒药物治疗丙型肝炎肝硬化早期抗病毒疗效及安全性临床实践研究[J].传染病信息, 2016, 29 (2) :81-84, 96.

[16]JI F, WANG W, DANG S, et al.Outcomes after sofosbuvir-containing regimens for hepatitis C virus in patients with decompensated cirrhosis:a real-world study[J].Infect Agent Cancer, 2017, 12:48.

[17]ZHANG XC, LI H, WANG J.Clinical effect of sofosbuvir combined with daclatasvir and ribavirin in treatment of hepatitis C cirrhosis[J].Chin Remed Clin, 2016, 16 (8) :1188-1190. (in Chinese) 张秀春, 李红, 王健.索菲布韦联合达卡他韦及利巴韦林治疗丙型肝炎肝硬化疗效观察[J].中国药物与临床, 2016, 16 (8) :1188-1190.

[18]ZHONG XQ, CHU XD.Clinical effect of direct-acting antiviral therapy in patients with chronic hepatitis C[J].Med Forums Basic, 2017, 21 (5) :581-582. (in Chinese) 仲小强, 储旭东.慢性丙肝直接抗病毒治疗临床观察[J].基层医学论坛, 2017, 21 (5) :581-582.

[19]WEI L, ZHANG M, XU M, et al.A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin[J].J Gastroenterol Hepatol, 2016, 31 (11) :1860-1867.

[20]LIU CH, LIU CJ, SU TH, et al.Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype1b infection in Taiwan[J].J Gastroenterol Hepatol, 2017.[Epub ahead of print]

[21]WANG BW, KANG W, XIE YM, et al.Clinical effect of 3D regimen (paritaprevir/ritonavir/ombitasvir combined with dasabuvir) in treatment-naive patients with genotype 1 b chronic hepatitis C[J].J Clin Hepatol, 2017, 33 (6) :1092-1095. (in Chinese) 王博文, 康文, 谢玉梅, 等.3D方案 (帕里瑞韦/利托那韦/比他韦联合达塞布韦) 治疗初治基因1b型慢性丙型肝炎患者的效果分析[J].临床肝胆病杂志, 2017, 33 (6) :1092-1095.

[22]WEI L.Chronic hepatitis C virus infection:current status and transition in China[J].Chin J Intern Med, 2014, 53 (9) :681-684. (in Chinese) 魏来.慢性丙型肝炎病毒感染:中国的现状和转折[J].中华内科杂志, 2014, 53 (9) :681-684.

[23]CURRY MP, O'LEARY JG, BZOWEJ N, et al.Sofosbuvir and Velpatasvir for HCV in patients with decompensated cirrhosis[J].N Engl J Med, 2015, 373 (27) :2618-2628.

[24]KWO PY, BADSHAH MB.New hepatitis C virus therapies:drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage renal disease[J].Curr Opin Organ Transplant, 2015, 20 (3) :235-241.

[25]KAWAKAMI Y, IMAMURA M, IKEDA H, et al.Pharmacokinetics, efficacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C:pilot study[J].J Viral Hepat, 2016, 23 (11) :850-856.

施引文献

资源附件(0)

访问统计